Anti-CD38 antibody for refractory acquired hemophilia A

Patients with acquired hemophilia A (AHA) are prone to bleeding symptoms due to decrease in factor (F)VIII activity caused by FVIII antibodies. Risk of severe bleeding in AHA is higher than that of hereditary hemophilia, so clearance of FVIII inhibitors is necessary for treatment, especially in refractory AHA. Daratumumab is currently a popular monoclonal antibody for clearing plasma cells and antibodies and is often used in multiple myeloma. Based on this, we report, for the first time, that 4 patients with AHA who were refractory to first- and second-line therapy were treated with daratumumab and achieved good responses. None of our 4 patients developed serious infections. Thus, we provide a new approach for treating refractory AHA.